Analyst Research Report Snapshot

Title:

NEUROSEARCH - HART DATA ANGST

Price:

$10.00

Provider:

Edison Investment Research

Date:

02 Nov 2010

Pages:

8

Type:

AcrobatPDF

Companies referenced:

NEUR.CO

Available for Immediate Download
Summary:

The Phase II HART study of Huntexil in Huntington’s disease showed some good evidence of efficacy but only a trend, rather than statistical significance, on its primary endpoint. Since the prior MermaiHD study produced a similar result, we presume regulators will require a second Phase III study. The question is whether this has to be conducted pre- or post-approval. Regulatory feedback should be known by Q111. NeuroSearch should be able to fund such a Phase III study if it has to be conducted prior to filing, but this would delay approval by two years, to late 2013.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.